东曜药业-B(1875.HK)公告，截至2024年12月31日止年度全年业绩，公司业绩超预期，全年营收人民币1,098,329千元，同比增长41%。2024年首次实现扭亏为盈，全年净利润达人民币34,757千元。造血能力持续增强，经营活动现金净额连续三年持续正向，2024年达人民币116,403千元。CDMO业务呈现强劲发展潜力，漏斗效应明显；得益于前沿的技术平台，强化前端引流，早期项目大幅增加。全年新增项目58个，其中ADC48个，累计至153个项目。全年成功获得2个pre-BLA(上市前关键临床及新药申报阶段项目)项目，累计在手8个，充分展示了公司CDMO后期商业化项目卓越能力，强化公司未来收入预期潜力。在手已签约未完成订单达人民币1.91亿元，同比增长39%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.